170 results about "Receptor interaction" patented technology

The invention discloses an intercellular signal transduction inference method and device based on optimal transmission of a knowledge graph, equipment and a medium, and relates to the technical field of genetic engineering. The source gene expression data of different cells in the source cell type and the target gene table data of different cells in the target cell type are found according to the cell type database. On the basis of the ligand-receptor interaction knowledge graph, obtaining various pathways with an interaction relationship between the source cell type and the target cell type, and constructing a pathway set; and with the aim of minimizing the total transmission cost, determining an optimal transmission cost matrix of each path in the path set by adopting an scKGOT algorithm. According to the method, the intercellular channel can be more conveniently deduced, and the intercellular communication can be deduced by accurately simulating the intercellular ligand-receptor signal channel.

The invention belongs to the field of bioinformatics, and relates to an improved integrated deep learning cell communication ligand-receptor interaction prediction method. The method comprises the following steps: firstly, carrying out extraction and dimensionality reduction on biological sequence features of a ligand and a receptor, and constructing multi-modal feature input; secondly, constructing an improved deep neural network branch, introducing a batch normalization layer and a Leaky ReLU activation function, solving the problems of gradient disappearance and neuronal necrosis, and improving regularization strength to prevent overfitting; meanwhile, an enhanced heterogeneous graph auto-encoder branch is constructed, the graph embedding dimension is remarkably expanded to improve the feature capacity, and full convergence of the model is ensured by increasing training rounds; thirdly, fusing the improved deep network with the prediction probability of a heterogeneous graph auto-encoder by adopting a weighted integration strategy; and finally, outputting a potential interaction relationship based on the fusion probability. By optimizing the architecture and the strategy, the prediction accuracy and robustness are remarkably improved, and a reliable tool is provided for analyzing a complex cell communication network.

The present invention provides a class of programmed cell death inhibitors, a preparation method therefor and a use thereof. Specifically, the present invention provides a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, the compound being as shown in Formula I. The present invention also provides a method for preparing the compound and a pharmaceutical composition comprising the compound or a use thereof in treating or preventing diseases or conditions associated with programmed cell death and / or human receptor-interacting protein 1 kinase (RIPK1).

The present invention relates to tetrahydrobenzo-isoquinoline sulfonamides derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FIERI receptor.

The invention provides a nano-drug for treating glioma as well as a preparation method and application of the nano-drug, and particularly, the nano-drug comprises a nano-carrier and a carrier drug. The nano-drug can interact with a receptor on a brain endothelial cell, enters a brain tumor microenvironment through an endocytosis way, promotes antigen presenting cell maturation, activates T cell anti-tumor immune response, and effectively inhibits tumor growth.

The present disclosure presents a general approach to engineering existing protein-protein interactions through domain addition and evolution. The disclosure teaches the creation of novel fusion proteins that include knottin peptides where a portion of the knottin peptide is replaced with a sequence that has been created for binding to a particular target. Such fusion proteins can also be bispecific or multi specific in that they can bind to and / or inhibit two or more receptors or receptor ligands. Knottins may be fused with an existing ligand (or receptor) as a general platform tor increasing the affinity of a ligand-receptor interaction or for creating a multi specific protein. In addition, the fusion proteins may comprise a knottin peptide fused to another protein where the other protein facilitates proper expression and folding of the knottin.

The present disclosure relates to systems, methods and compositions for decoding ligand-receptor interactions, for delivering nucleic acids and proteins into target cells and for performing single cell multiomics. Disclosed are engineered lentiviruses displaying ligands that deliver cargo into target cells upon cognate receptor-ligand interaction. Also disclosed are compositions and methods including pMHC or antigen epitopes displaying lentiviruses for identifying pMHC / T-cell receptors and antigen / B-cell receptor interactions.

The present invention provides humanized monoclonal antibodies that recognize human Nectin-2 with high affinity and specificity and inhibit its binding to CD112R. These antibodies carry cytotoxic payload and do not interact with Fc gamma receptors. The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy.

The invention relates to RIP1 inhibiting compounds and methods of making and using the same. In particular, disclosed herein are kinase inhibitory compounds, such as receptor interacting protein-1 (RIP1) kinase inhibitor compounds, and pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions and / or combinations may be used to treat or prevent kinase-related diseases or disorders, particularly RIP1-related diseases or disorders.

The present disclosure is directed to the combination or combined use of (i) a compound able to disrupt or impede netrin-1 / netrin-1 receptors interaction or netrin-1-mediated receptor dimerization, also called herein a NTN1 neutralizing agent, which compound may be an antibody binding to netrin-1 or anti-netrin-1 antibody, and (ii) an immune checkpoint inhibitor, in the treatment of cancer. The composition may comprise an anti-netrin-1 antibody and an immune checkpoint inhibitor, for use as an anticancerous drug with a simultaneous, separate or sequential administration of the anti-netrin-1 antibody and the immune checkpoint inhibitor to a patient.

The invention provides CD27 agonists comprising a first component that is an anti-CD27 antibody, or antigen-binding fragment thereof, linked to a second component comprising one or more cross-linking moieties. At least one of the cross-linking moieties does not bind to an Fc receptor and the CD27 agonist stimulates T cell activity without the need for Fc receptor interaction. The cross-linking molecule(s) can be, for example, an anti-CD27, antibody, or antigen-binding fragment thereof, that can be the same or different than the first component. Alternatively, the cross-linking molecule(s) can be a CD27 ligand or a molecule (e.g., antibody) that binds a molecule on a cell such as a T cell, a tumor cell or a stromal cell. Pharmaceutical compositions comprising the CD27 agonists, and methods of using the CD27 agonists, are also provided.

Disclosed herein are kinase inhibitory compounds, such as receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, and pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions and / or combinations can be used to treat or prevent kinase-related diseases or conditions, particularly RIP1-related diseases or conditions.

A dynamic antimicrobial hydrogel based on natural receptor-ligand recognition, and a preparation method and use thereof are provided. A ligand vancomycin and a receptor AA-based material each are first modified with a modification material, and then a photoinitiator is added to prepare a hydrogel material under irradiation of ultraviolet (UV) light. In the hydrogel, a three-dimensional (3D) network structure is formed through crosslinking. After undergoing a fracture under an external pressure, the hydrogel can rapidly heal itself through crosslinking due to a ligand-receptor interaction and a multi-hydrogen-bond interaction, which bio-mimicks a natural ligand-receptor interaction to realize the dynamics of the hydrogel material. The high antiomicrobial activity of vancomycin imparts the functionality of the hydrogel material; and the physiologically-derived monomer improves the biocompatibility and reduces the biological toxicity.

The present invention relates to a polymer conjugate comprising a ULA polymer a) and one or more polypeptides b), wherein the polypeptides are conjugated to the ULA polymer, and the conjugate is coated on the surface of a device for culturing cells. The peptides can interact with receptors on the surface of the cells, while the polymer prevents non-specific binding of the cells to the surface of the device.

The present invention provides humanized monoclonal antibodies that recognize human Nectin-2 with high affinity and specificity and inhibit its binding to CD112R. These antibodies carry cytotoxic payload and do not interact with Fc gamma receptors. The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy.

This invention relates to a novel use of IL-1β-ligand / IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and / or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and / or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and / or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Provided are a compound as a receptor-interacting protein (RIP) inhibitor, a preparation method therefor, and a use thereof, relating to the field of chemical medicines. The compound is a compound as represented by formula (I), or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a prodrug thereof. The compound has good inhibitory activity on humanized RIP1 kinase, and can be used for preparing drugs for resisting inflammation, resisting tumors and the like.

Disclosed herein are kinase inhibitory compounds, such as receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, and pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and / or combinations can be used to treat or prevent kinase-related diseases or conditions, particularly RIP1-related diseases or conditions.

The invention discloses a double-gene engineered mesenchymal stem cell and application thereof, and relates to the technical field of biological medicines. According to the double-gene engineered mesenchymal stem cell provided by the invention, CXCR4 and TNFSF14 proteins are co-expressed by the mesenchymal stem cell, and the mesenchymal stem cell shows enhanced tumor tropism and immune-mediated anti-tumor activity. Specifically, based on the principles that CXCR4 can enhance the active homing ability of mesenchymal stem cells to gastric cancer lesions expressing ligands SDF-1 (SDF-1 / CXCL12) of the mesenchymal stem cells, TNFSF14 (LIGHT can interact with HVEM and LT betaR receptors to promote activation of T cells and NK cells and the like, the mesenchymal stem cells co-expressing CXCR4 and LIGHT overcome the defects that natural MSCs are insufficient in targeting ability and weak in immune activation ability; the excellent anti-tumor effect is realized.

The present invention discloses a recombinant human fibronectin with soothing composite function and its preparation method and application. The recombinant human fibronectin with soothing composite function has an amino acid sequence as shown in SEQ ID NO.1. The present invention adds the hyaluronic acid interaction segment of human fibronectin while retaining the main segment of human fibronectin cell adhesion and cell integrin receptor interaction, and connects the two domains with a flexible "linker" amino acid sequence GGS to form a recombinant human FN protein with composite function. In addition to the core characteristics of traditional recombinant fibronectin, the recombinant human fibronectin also has the function of soothing cell stimulation. The recombinant human fibronectin prepared by the present invention will have a good effect in soothing skin irritation in the field of functional active skin care products.

The present invention relates to compounds of formula (I), pharmaceutical compositions containing them, processes for their preparation, and their use as receptor interacting protein kinase 1 (RIPK1) inhibitors. The invention also relates to application of the compound or the composition containing the compound to treatment or prevention of related diseases or symptoms mediated by RIPK1. # imgabs0 #

A compound represented by formula (I), isomers or pharmaceutically acceptable salts thereof, and application thereof in the preparation of drugs for treating diseases related to RIP-1 (receptor interacting protein) kinase.

The application discloses double-gene engineered mesenchymal stem cells and application thereof, relates to the technical field of biological medicine. The double-gene engineered mesenchymal stem cells provided by the application co-express CXCR4 and TNFSF14 proteins, exhibit enhanced tumor tropism and immune-mediated anti-tumor activity. Specifically, based on the principle that CXCR4 can enhance the active homing ability of mesenchymal stem cells to gastric cancer lesions expressing its ligand SDF-1 (SDF-1 / CXCL12), and TNFSF14 (LIGHT) can interact with HVEM and LTbetaR receptors to promote the activation of T cells and NK cells, the mesenchymal stem cells co-expressing CXCR4 and LIGHT overcome the defects of insufficient targeting of natural MSCs and weak immune activation ability, and have excellent anti-tumor effect.

The invention provides a granulocyte-macrophage colony stimulating factor antibody and application thereof, and belongs to the technical field of biological medicine. A granulocyte-macrophage colony stimulating factor (GM-CSF) antibody or fragment has high affinity, can effectively block GM-CSF / GM-CSF receptor interaction, and has low immunogenicity. The GM-CSF antibody or fragment can be used for preventing and / or treating diseases caused by human GM-CSF or detecting human GM-CSF protein or diagnosing related diseases caused by the human GM-CSF protein.

Disclosed herein are methods, compositions, systems, and kits related to functional testing of polypeptide-target interactions, such as antigen / immune receptor interactions, in a single-cell format.

The present disclosure provides compounds, including piperazine heterocyclic amide urea compounds (including the corresponding sulfonamides), that inhibit cell necrosis and / or human receptor-interacting protein 1 kinase (RIP1), and pharmaceutically acceptable salts, hydrates, and stereoisomers thereof. The compounds of the present invention are used in pharmaceutical compositions and methods of use and manufacturing, including treating a person in need thereof with an effective amount of a compound or composition of the present invention and detecting a resulting improvement in the person's health or condition.

The present invention pertains to the treatment of diseases associated with a dysregulated immune response such as auto immune disorders, inflammatory diseases or pathological immune responses as adverse effects of medical treatments. In particular the invention provides a combined use of inhibitors of Receptor-interacting serine / threonine-protein kinase (RIPK1) and inhibitors of Inhibitor of κB (IκB) Kinase (IKK) in subjects suffering from such disorders. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention.

A polypeptide based on RIP3 methylation modification and application thereof in cell necroptosis-related diseases are provided, belonging to the technical field of biomedicine. The polypeptide for inhibiting intestinal inflammatory injury (TAT-mRIP3-SDMA) is formed by connecting cell-penetrating peptide TAT and methylated RIP3 polypeptide.

Antibodies that target VZV glycoprotein E (gE) bind to recombinant gE with high affinity, bind to gE on the surface of VZV infected cells, interact with immune system effectors (e.g., Fc receptors), mediate antibody-dependent cellular cytotoxicity (ADCC) as well as Antibody Dependent Cellular Phagocytosis (ADCP), and prevent VZV infection of cells.